352 related articles for article (PubMed ID: 33498923)
1. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
[TBL] [Abstract][Full Text] [Related]
4. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
6. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
[TBL] [Abstract][Full Text] [Related]
7. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.
Loschwitz J; Jäckering A; Keutmann M; Olagunju M; Eberle RJ; Coronado MA; Olubiyi OO; Strodel B
Bioorg Chem; 2021 Jun; 111():104862. PubMed ID: 33862474
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
[TBL] [Abstract][Full Text] [Related]
9. A Bioluminescent 3CL
Mathieu C; Touret F; Jacquemin C; Janin YL; Nougairède A; Brailly M; Mazelier M; Décimo D; Vasseur V; Hans A; Valle-Casuso JC; de Lamballerie X; Horvat B; André P; Si-Tahar M; Lotteau V; Vidalain PO
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578395
[TBL] [Abstract][Full Text] [Related]
10. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
11. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
12. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.
O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC
Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599
[TBL] [Abstract][Full Text] [Related]
13. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y
Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395
[No Abstract] [Full Text] [Related]
14. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL
Stille JK; Tjutrins J; Wang G; Venegas FA; Hennecker C; Rueda AM; Sharon I; Blaine N; Miron CE; Pinus S; Labarre A; Plescia J; Burai Patrascu M; Zhang X; Wahba AS; Vlaho D; Huot MJ; Schmeing TM; Mittermaier AK; Moitessier N
Eur J Med Chem; 2022 Feb; 229():114046. PubMed ID: 34995923
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M
Moghadasi SA; Esler MA; Otsuka Y; Becker JT; Moraes SN; Anderson CB; Chamakuri S; Belica C; Wick C; Harki DA; Young DW; Scampavia L; Spicer TP; Shi K; Aihara H; Brown WL; Harris RS
mBio; 2022 Jun; 13(3):e0078422. PubMed ID: 35471084
[TBL] [Abstract][Full Text] [Related]
17. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
18. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
[TBL] [Abstract][Full Text] [Related]
19. Punicalagin and zinc (II) ions inhibit the activity of SARS-CoV-2 3CL-protease in vitro.
Saadh MJ; Almaaytah AM; Alaraj M; Dababneh MF; Sa'adeh I; Aldalaen SM; Kharshid AM; Alboghdadly A; Hailat M; Khaleel A; Al-Hamaideh KD; Abu Dayyih W
Eur Rev Med Pharmacol Sci; 2021 May; 25(10):3908-3913. PubMed ID: 34109605
[TBL] [Abstract][Full Text] [Related]
20. Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL
Cesar Ramos de Jesus H; Solis N; Machado Y; Pablos I; Bell PA; Kappelhoff R; Grin PM; Sorgi CA; Butler GS; Overall CM
J Virol; 2024 Jun; 98(6):e0004924. PubMed ID: 38742901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
